ArticleAnnals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc2025
Effect of Dapagliflozin Treatment on Index of Cardiac Electrophysiological Balance in Patients With Heart Failure With Reduced Ejection Fraction.
Article in Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Index of cardiac electrophysiological balance in patients with vasovagal syncope confirmed by head-up tilt test.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDapagliflozin (DAPA), a sodium-glucose cotransporter-2 (SGLT2) inhibitor, may attenuate the risk of ventricular arrhythmia (VA) through its antiarrhythmic properties in patients with heart failure with reduced ejection fraction (HFrEF). The antiarrhythmic mechanisms of SGLT2 inhibitors are not fully known. Recently, the index of cardiac electrophysiological balance (ICEB) has been posited as a robust indicator for predicting VA risk. ICEB reflects the balance between ventricular depolarization and repolarization. This study was conducted to investigate the effects of DAPA treatment on ICEB in a cohort of patients with HFrEF.
methodsA total of 235 HFrEF patients undergoing DAPA treatment were enrolled in the study. Each participant underwent a comprehensive 12-lead electrocardiography (ECG) assessment prior to treatment initiation and approximately 6 months posttreatment. ICEB values were compared before and after treatment.
resultsThe analysis revealed a statistically significant reduction in the QT interval (427.51 ± 13.87 vs. 347.75 ± 11.21 ms, p < 0.001), corrected QT interval (QTc) (458.34 ± 29.71 vs. 393.37 ± 13.21 ms, p < 0.001), T peak-to-end (Tp-e) interval (85.41 ± 3.52 vs. 71.18 ± 3.16 ms, p < 0.001), Tp-e/QTc ratio (0.186 ± 0.009 vs. 0.180 ± 0.003, p < 0.001), ICEB (4.59 ± 0.65 vs. 3.77 ± 0.15, p < 0.001), following approximately 6 months of DAPA treatment.
conclusionIn addition to ventricular repolarization distribution indices, the regression of the ICEB values after DAPA treatment in patients with HFrEF shows that DAPA treatment improves the balance between ventricular depolarization and repolarization and reduces the risk of VA in these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.